Article
Multidisciplinary Sciences
Hye Yeon Koo, Su-Min Jeong, Mi Hee Cho, Sohyun Chun, Dong Wook Shin, Jinsung Park
Summary: Aspirin and metformin use may be associated with lower prostate cancer incidence and mortality, while statins are not associated with either.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Suzan Brancher, Nathalie C. Stoer, Elisabete Weiderpass, Ronald A. M. Damhuis, Tom B. Johannesen, Edoardo Botteri, Trond-Eirik Strand
Summary: The study found that pre-diagnostic metformin use was associated with improved LCSS in squamous cell carcinoma (SCC) patients, while post-diagnostic metformin use was associated with improved LCSS and OS in all patients. There was a dose-response relationship in all patients regarding the cumulative use of metformin, suggesting a potential role of metformin in lung cancer treatment.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Bo Bin Lee, Dongho Kim, Yujin Kim, Joungho Han, Young Mog Shim, Duk-Hwan Kim
Summary: This study found that metformin inhibits the expression of DNMTs in non-small cell lung cancer cells by upregulating miR-148/-152 family members.
CLINICAL EPIGENETICS
(2023)
Article
Oncology
Jiaojiao Zheng, Giola Santoni, Shao-Hua Xie, Jesper Lagergren
Summary: The study suggests that the use of metformin in diabetes patients diagnosed with gastric adenocarcinoma may reduce the risk of disease-specific and all-cause mortality, particularly in female patients, patients with tumor stage III or IV, and those with the least comorbidity.
BRITISH JOURNAL OF CANCER
(2021)
Article
Medical Informatics
Ash Kieran Clift, Gary S. Collins, Simon Lord, Stavros Petrou, David Dodwell, Michael Brady, Julia Hippisley-Cox
Summary: This study aims to develop a prognostic model that accurately predicts the 10-year risk of breast cancer mortality in female individuals without breast cancer at baseline.
LANCET DIGITAL HEALTH
(2023)
Review
Pharmacology & Pharmacy
Xiaofeng Luo, Xi Chen, Lin Wang, Bowen Yang, Shuang Cai
Summary: The combination of metformin and antineoplastic agents showed significant improvement in overall survival and progression-free survival outcomes in lung cancer patients, especially in non-diabetic patients. However, further investigation is needed to confirm these findings, as limited data from randomized controlled trials showed no differences in survival outcomes.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Keying Jing, Huijuan Zhao, Jun Cai, Lianlian Chen, Peiming Zheng, Libo Ouyang, Gang Li, Rong Wang
Summary: This study investigated the correlation between autoantibodies and outcomes in patients with lung cancer. The results showed that patients with autoantibodies had a reduced risk of death and longer survival time compared to patients without autoantibodies.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Shin-Mao Lin, Szu-Chun Yang, Tzu-I. Wu, Jung-Der Wang, Li-Fan Liu
Summary: This study quantified the societal impact of disability in patients with non-small cell lung cancer (NSCLC) by estimating disability-free life expectancy (DFLE) and loss-of-DFLE. The findings showed that advanced stage NSCLC had a stronger effect on patients compared to old age. Quality-adjusted life expectancy (QALE) was shorter than DFLE due to discomfort and depression. Early diagnosis of NSCLC may help decrease the burden of long-term care.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Yeshwanth Reddy Vedire, Sarbajit Mukherjee, Sumedha Dondapati, Sai Yendamuri
Summary: This study aimed to investigate the association between visceral obesity and disease recurrence and survival in early-stage colorectal cancer (CRC) patients. The researchers also examined if this association is influenced by metformin use. The results showed that visceral obesity, but not BMI, is associated with recurrence risk and poorer survival in stage I/II CRC. Interestingly, this association is influenced by metformin use.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Kathrin Kahnert, Stefan Andreas, Christina Kellerer, Johanna Lutter, Tanja Lucke, Oender Yildirim, Mareike Lehmann, Jochen Seissler, Juergen Behr, Marion Frankenberger, Robert Bals, Henrik Watz, Tobias Welte, Franziska C. Trudzinski, Claus F. Vogelmeier, Peter Alter, Rudolf A. Joerres, Thomas Bahmer, Burkhard Bewig, Ralf Ewert, Beate Stubbe, Joachim H. Ficker, Christian Grohe, Matthias Held, Markus Henke, Felix Herth, Anne-Marie Kirsten, Henrik Watz, Rembert Koczulla, Juliane Kronsbein, Cornelia Kropf-Sanchen, Christian Herzmann, Michael Pfeifer, Winfried J. Randerath, Werner Seeger, Michael Studnicka, Christian Taube, Hartmut Timmermann, Bernd Schmeck, Claus Vogelmeier, Hubert Wirtz
Summary: This study examined the association between metformin treatment and lung function decline in COPD patients. The findings suggest that COPD patients receiving metformin had a slower decline in lung diffusing capacity, supporting the hypothesis of the anti-aging effects of metformin.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Suzan Brancher, Ana Elisa Ribeiro, Tatiana Natasha Toporcov, Elisabete Weiderpass
Summary: The use of metformin has been found to have a positive impact on the survival of lung cancer patients in observational studies, but no significant effect was observed in randomized clinical trials. Further studies utilizing time-dependent analysis and well-designed RCTs are needed to provide consistent results for the association between metformin use and lung cancer survival.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Hadeer Ehab Barakat, Raghda R. S. Hussein, Ahmed Abdullah Elberry, Mamdouh Ahmed Zaki, Mamdouh Elsherbiny Ramadan
Summary: The study evaluated the anticancer activity and safety of metformin combined with neoadjuvant chemotherapy in locally advanced BC patients, showing that metformin can improve tumor responses, especially when associated with higher serum concentrations.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Di Li, Chaoqiang Deng, Fangqiu Fu, Jinsong Bai, Yuan Li, Yang Zhang, Haiquan Chen
Summary: This study discovered that prior cancer has an impact on newly diagnosed lung cancer, especially in patients with clinically curable lung cancer. It is important for clinicians to pay attention to this effect and improve the management of these patients for a better prognosis.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Di Li, Chaoqiang Deng, Fangqiu Fu, Jinsong Bai, Yuan Li, Yang Zhang, Haiquan Chen
Summary: This study, using a large study population, found that prior cancer had a negative impact on overall survival in lung cancer patients, especially in early-stage patients. The extent of this impact varied depending on the type and interval time of prior cancer.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Abdelnour H. Alhourani, Tia R. Tidwell, Ansooya A. Bokil, Gro Rosland, Karl Johan Tronstad, Kjetil Soreide, Hanne R. Hagland
Summary: This study investigated the impact of glucose concentration on cancer cells' response to metformin, highlighting the diverse reactions based on different growth rates and metabolic phenotypes under varying glucose conditions. The results demonstrate the importance of growth conditions in determining the effectiveness of metabolic drugs like metformin in cancer therapy.
SCIENTIFIC REPORTS
(2021)
